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Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer that is clinically deﬁned as lacking estrogen and
progesterone receptors, as well as being ERBB2 (HER-2) negative. Without speciﬁc therapeutic targets, TNBC carries a worse
prognosis than other types of breast cancer in the absence of therapy. Research has now further diﬀerentiated breast cancer into
subtypes based on genetic expression patterns. One of these subtypes, basal-like, frequently overlaps with the clinical picture
of TNBC. Additionally, both TNBC and basal-like breast cancer link to BRCA mutations. Recent pharmaceutical advances have
created a class of drugs, poly(ADP-ribose) polymerase (PARP) inhibitors, which are showing potential to eﬀectively treat these
patients.TheaimofthispaperistosummarizethebasisbehindPARPinhibitorsandupdatethecurrentstatusoftheirdevelopment
in clinical trials for the treatment of TNBC.
1.Introduction
Breast cancer is a multifaceted, heterogeneous disease whose
treatment is evolving as genetic proﬁles shed more light
on potential targets. The understanding of breast cancer
became more complex with Perou et al.’s 2000 publication
detailing the classiﬁcation of breast cancer based on gene-
expressionassays[1].Amongthisclassiﬁcationwasthebasal-
like subtype, described as frequently (but not always) being
ER, PR, and HER-2 deﬁcient while also expressing basal
cytokeratins 5/6 and 17 and epidermalgrowth factor(EGFR)
[1, 2]. These basal-like breast cancers make up 17 to 37%
of all breast cancers [2–4]. Having genetic proﬁles outlining
the inherent diﬀerences in breast cancer has allowed for new
research paths attempting to develop novel therapeutics that
are subtype dependent.
The deﬁnition of triple-negative breast cancer is based
on clinical observations; the tumor must lack estrogen
receptors (ERs), progesterone receptors (PRs), and hormone
epidermal growthfactorreceptortype 2(HER-2) expression.
These tumors are particularly vexing for physicians because
there are no known endocrine targets nor are there speciﬁc
receptors to block. Women diagnosed with TNBC tend to
be younger [5] and are more likely to present with poorly
diﬀerentiated tumors [6]. Although TNBC is responsive to
chemotherapy and features a higher pathologic complete
response (pCR) rate compared to other breast cancer types
(in the presence of neoadjuvant therapy) [7], the prognosis
for TNBC patients is still poor [7, 8].
There are many similarities between TNBC and basal-
like breast cancer, but the two terms are not synonymous
(Figure 1). They share demographic characteristics such as
age of ﬁrst menarche and increased incidence in the African-
American [9] and Hispanic [10] female population. It has
been noted that roughly 80% of TNBC tumors are basal-like
breast cancers [11]. However, immunohistochemical studies
have shown that 17–40% of basal-like breast cancers do not
have a triple-negative phenotype [12]. Up to 20% of basal-
like breast cancers actually express ER or HER-2 to some
extent [13].
One important similarity between TNBC and basal-
like breast cancer is the incidence of mutations in the2 International Journal of Breast Cancer
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Figure 1: A Venn diagram representing the connection of TNBC,
basal-like breast cancer, and BRCA-mutated breast cancer.
breast cancer susceptibility gene 1 and 2 (BRCA1 and 2).
BRCA mutations are only 2-3% of all breast cancers but
signify an increased lifetime risk of breast and ovarian
cancer [14]. Somatic BRCA mutations or inactivation of
the gene can also occur. It is estimated that methylation of
the BRCA1 promoter can be found in 11–14% of sporadic
breast cancers [15–17]. BRCA1 is a key player in mammary
gland development [18], and both BRCA1 and BRCA2 are
connected with DNA repair [14]. A majority of tumors
in women with BRCA mutations feature similar expression
patternsasbasal-liketumors[18–20],cloudingthepictureof
where BRCA-mutated cancers, basal-like breast cancers, and
TNBC originate (Figure 1).
Researchers have found the links between TNBC, basal-
like breast cancer, and BRCA mutations to be a potential
source of directed therapy. One notable avenue is through
synthetic lethality. This is a strategy to target and kill speciﬁc
cell types, without collateral damage. It is achieved by
locating a gene that, when inhibited, will kill cancerous cells
that contain a speciﬁc genetic signature. The inhibitor would
not damage normal cells that lack the cancer-speciﬁc gene.
The design and exploration of poly(ADP-ribose) polymerase
(PARP) inhibitors have emerged as a potential target to cause
synthetic lethality in cancerous cells while sparing normal
mammary tissue. The aim of this paper is to discuss the
molecular basis behind PARP inhibitors and an update on
their current status in several clinical trials.
2.PARP1 Inhibitors
Poly(ADP-ribose) polymerase (PARP) is a nuclear protein
that is activated in the presence of DNA damage. While
severalPARPproteinshavebeendetected,PARP1andPARP2
have been associated with DNA stability [21]. When single
strand DNA (ssDNA) damage occurs, it is identiﬁed and
repaired by a cellular process that includes PARP and base
excision repair [22]. If ssDNA breaks are not repaired (e.g.,
PARP inhibition), the breaks build up and are converted
at the replication fork to double-strand DNA (dsDNA)
breaks [23–25]. At this point, homologous recombination
or nonhomologous end joining repairs the double-stranded
breaks in DNA [23, 25].
Homologous recombination is mediated by several fac-
tors, including BRCA1, BRCA2, and RAD51 [26–28]. Cells
deﬁcient in functioning homologous recombination, such
as ones with defective BRCA1 and/or BRCA2 genes, are
forced into less precise repair pathways that make them more
susceptible to cell death when overwhelmed with defects to
repair [29]. These alternate pathways include nonhomolo-
gous end joining. The incorrect pairing of ends of DNA
then possibly leads to genomic instability, ultimately ending
in apoptosis (Figure 2). Interestingly, PARP is also involved
in dsDNA repair in combination with nonhomologous end
joining, so PARP inhibition also hinders the cell’s other
repair routes [24]. PARP1 inhibitors are being investigated
as pharmacologic interventions for metastatic TNBC due
to a theory of selectivity: if only BRCA-defective genes
are terminated, then other cells that maintain a normal,
functioning BRCA allele will not be killed by a PARP
inhibitor. This synthetic lethality is being developed to create
a new class of drugs that aim to eﬃciently kill cancer cells.
3.CurrentTherapeuticStrategy
SeveralPARP1inhibitorsarebeingstudiedattheclinicaltrial
level, and this paper will focus speciﬁcally on iniparib, ola-
parib, and veliparib (Table 1, http://www.clinicaltrials.gov/).
Results of an open-label phase II trial for iniparib (BSI-201,
Sanoﬁ-Aventis) combined with chemotherapy on metastatic
TNBC patients were recently published [30]. This trial com-
pared the use of gemcitabine and carboplatin alone versus
those two agents and iniparib. The median progression-free
survival increased when iniparib was added, from 3.6 to 5.9
months. The median overall survival was also signiﬁcantly
increased in the iniparib group, up to 12.3 months from 7.7
months. A complete or partial response was seen in 56% of
patients receiving iniparib, while only 34% exhibited such a
response in the gemcitabine/carboplatin arm. Common side
eﬀects seen amongst the 116 patients were nausea, fatigue,
anemia, and neutropenia. It is notable that these side eﬀects
did not increase when iniparib was added to the regimen,
suggesting that the side eﬀects originate from gemcitabine
and/or carboplatin.
A notable component of this study is that BRCA1/2
status was not assessed on the patients. Domagala et al. have
claimed that 18% of BRCA1-associated cancers have low or
no nuclear expression of PARP1 [32] and low PARP1 expres-
sion in 21% of triple-negative BRCA1-associated breast
cancers [33]. When looking at cytoplasmic and nuclear
PARP,anothergrouphasobserveditspresenceinallintrinsic
types of breast cancer, albeit with diﬀerent frequencies [34].
There was a signiﬁcant correlation between cytoplasmic and
nuclear PARP in that study. Clearly, the expression pattern
and full mechanism of PARP1 needs to be investigated to
better understand if it will be an eﬀective target for TNBC.
At this year’s meeting of the American Society of Clinical
Oncology, O’Shaughnessy and colleagues presented their
results of the phase III iniparib trial. This trial enrolled 519
women and again looked at gemcitabine and carboplatinInternational Journal of Breast Cancer 3
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Figure 2: Depiction of BRCA mutations and PARP1 inhibitors blocking DNA repair and causing cell death [31]. Copyright © 2009
Massachusetts Medical Society. All rights reserved.
Table 1: Partial list of ongoing clinical trials for PARP inhibitors on TNBC.
Drug/company Trial ID Trial Phase
Olaparib (AZD2281)/AstraZeneca
NCT01116648 Cediranib and olaparib II
NCT00647062 AZD2281 and carboplatin I
NCT00516724 In combination with carboplatin and/or paclitaxel I
NCT00707707 In combination with paclitaxel I
NCT00679783 In known BRCA/TNBC II
Iniparib (BSI-201)/Sanoﬁ-Aventis
NCT01173497 Iniparib + irinotecan II
NCT00813956 Neoadjuvant with gemcitabine and carboplatin II
NCT01045304 Metastatic with gemcitabine and carboplatin II
NCT01204125 Neoadjuvant with paclitaxel II
NCT01130259 In combination with gemcitabine and carboplatin III
Veliparib (ABT-888)/Abbott
NCT01009788 With temozolomide II
NCT01104259 With cisplatin and vinorelbine ditartrate I
NCT01306032 With cyclophosphamide II
NCT01042379 I-SPY2 trial II
NCT01251874 With carboplatin I
Data obtained from http://www.clinicaltrials.gov, June 15, 2011.
versus the same regimen with added iniparib. The results
did ﬁnd an increase in progression-free survival amongst
the iniparib/gemcitabine/carboplatin arm (5.1 versus 4.1,
P = 0.027), but this did not achieve the prespeciﬁed criteria
for signiﬁcance (P = 0.01) [35]. A possible explanation
behind the change in results from phase II to phase III is
that the heterogenous nature of TNBC will continue to make
ﬁnding a single agent problematic in treating all comers. By
not stratifying the patients based on BRCA status or TNBC
subtype, it leaves questions as to which patients will truly
beneﬁt from this drug and which have a genetic makeup
that is not conducive to iniparib. Iniparib is continuing to
be studied in other phase III clinical trials, including its
eﬀects on nonsmall cell lung cancer and ovarian cancer.
Iniparib evidently is not being discontinued completely from
breast cancer research; rather, the drug maker has continued
with phase II trials analyzing diﬀerent doses, schedules, and
chemotherapy combinations.
Olaparib (AZD2281, AstraZeneca) is another PARP1
inhibitor that is being tested on various cancers, including
breast. Preclinical models showed an increased selective
potency for this compound [36]. The subsequent phase I
trial revealed 400mg twice daily to be the maximum dose.
With a BRCA1- or BRCA2-defective cohort of 22 patients,
antitumor eﬃcacy was observed once the dosages reached
100mg twice daily [37]. Results of a phase II trial detailed
how olaparib is eﬀective in breast cancer patients with a
BRCA1 or BRCA2 mutation and advanced disease [38].
While admittedly not a ﬂawless design, such as lacking
randomization, the results showed promise. All patients
in the study had locally advanced breast cancer (LABC)
or metastatic breast cancer. For the TNBC and BRCA1/2
carrier patients in this cohort, twice daily 400mg dosages of
olaparib were more eﬀective than twice daily 100mg dosages
when analyzing objective response (54% versus 25%) and
progressive disease (15% versus 31%). These data were4 International Journal of Breast Cancer
observed,butitmustbenotedthatthistrialwasnotdesigned
or powered for this comparison. When looking at all of
the women in the trial, 41% of the BRCA1- or BRCA2-
mutated breast cancer patients had an objective response
when assigned 400mg twice-daily olaparib.
Despite these encouraging results, London-based drug
maker AstraZeneca has decided to suspend olaparib prior to
a phase III trial. AstraZeneca has shifted its olaparib focus to
ovarian cancer and currently has a phase II trial to study its
eﬀects on that cancer type [39].
Veliparib (ABT-888, Abbot Laboratories) has been inves-
tigated as a single agent [40] and also has been shown to
improve laboratory outcomes when paired with platinum
agents and radiotherapy. Donawho et al. were able to
show that 5 and 25mg/kg/d of veliparib combined with
cisplatin were signiﬁcant in tumor regression of murine
models compared to cisplatin alone [41]. 10mg/kg/d of
veliparib was also shown to be eﬀective in combination
with carboplatin when compared to carboplatin alone. In
addition to improving the eﬀectiveness of platinum agents
on murine models of breast cancer, veliparib has shown
to assist in radiation therapy. In mice, 3Gy with added
veliparib was signiﬁcantly more eﬀective in inducing early
cellularsenescencethanjusttheradiationalone[42].Aphase
II trial recently studied the eﬀects of veliparib combined
with temozolomide on metastatic breast cancer and included
TNBC patients [43]. Of the 51 patients in the study, only
8 had a BRCA mutation. Progression-free survival was 5.5
months in the BRCA-mutated group versus 1.8 months
for patients without a BRCA mutation. This suggests that
veliparib might only be eﬀective in patients carrying BRCA
mutations.
4. Conclusion
TNBC is a clinical term used to describe women whose
tumors lack expression of ER, PR, and HER-2. This subset
ofbreastcancerpartiallyﬁtsintoamolecularsubtypeknown
asbasal-likebreastcancer.Regardlessofwhetheronelooksat
datathroughaTNBCorbasal-likespectrum,theprognosisis
worse compared to other subtypes. While there is no speciﬁc
treatment regimen for TNBC patients, neoadjuvant therapy
has been eﬀective in achieving complete pathologic response
(pCR) that subsequently correlates to improved outcome
[7, 44]. TNBC patients who achieve pCR had similar overall
survival rates to non-TNBC patients who achieved pCR.
However, TNBC patients that did not reach pCR had a worse
outcomecomparedto non-TNBC patients that did not reach
pCR.
Therapeutic options for TNBC have the potential to
drastically increase in the near future. Combinations of
platinum compounds for neoadjuvant therapy are being
tested in various clinical trials. Epidermal growth factor
receptors (EGFRs) are noted in 45–70% of TNBC [45, 46],
resulting in EGFR antagonists such as cetuximab (Merck
Serono) to be explored. Linderholm et al. noted VEGF to be
increased in their TNBC patients compared to non-TNBC
[47], and the antiangiogenic agent bevacizumab is being
studied in combination with several chemotherapy agents
in clinical trials. Still other emerging avenues for treatment
include mammalian target of rapamycin (mTOR) inhibitors
and SRC tyrosine kinase inhibitors.
Many potential therapeutic agents are in the pipeline
in laboratories worldwide, but PARP inhibitors have the
potential to alter the outcome of TNBC patients. In addition
to iniparib, olaparib, and veliparib, there are more being
constructed.TheseincludeCEP-9722(Cephalon),INO-1001
(Genentech), PF-01367338 (Clovis/Pﬁzer), and MK-4827
(Merck).
Several challenges must still be met to continue advanc-
ing PARP inhibitors. Most notably is the fact that recent
trial data have landed huge blows to the momentum of
PARP inhibitors for breast cancer. At the 2011 ASOC,
it was announced that iniparib did not perform at its
expected eﬀectiveness in a phase III trial with metastatic
TNBC patients. AstraZeneca has maintained an interest in
PARP inhibitors, but is doing so through further trials in
other organs, such as ovarian. Yet another complication that
has emerged is resistance to PARP inhibitors that is being
observed in the laboratory [48]. Norquist et al. recently
reported to observe cell lines with BRCA1/2 restoration
mutations exhibiting resistance to platinum therapy in
patients with hereditary ovarian cancer. They also observed
these restoration mutations to predict resistance to PARP
inhibitors, but did not have a large sample size [49]. More
research must be done on these compounds to prepare for
these and other, unknown, complications.
It will be imperative to continue exploring the pathway
connectingTNBC,basal-likebreastcancer,andBRCA.There
appears to be more questions to explore and compounds
to test in the TNBC population with these therapeutics.
Also, further testing is necessary to identify the optimal
doses of not only the PARP inhibitor but also any combined
chemotherapy. These key components of PARP inhibitor
development will hopefully improve the quality of this
class of cancer-ﬁghting drugs and provide hope for patients
currently facing such bleak diagnoses.
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